​

Stoke Therapeutics (STOK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

STOK Stock Forecast

Stoke Therapeutics (STOK) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $28.00, with a high of $28.00 and a low of $28.00. This represents a 17.25% increase from the last price of $23.88.

$5 $10 $15 $20 $25 $30 High: $28 Avg: $28 Low: $28 Last Closed Price: $23.88

STOK Stock Rating

Stoke Therapeutics stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (73.33%), 4 Hold (26.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 4 11 0 Strong Sell Sell Hold Buy Strong Buy

STOK Price Target Upside V Benchmarks

TypeNameUpside
StockStoke Therapeutics17.25%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts112
Avg Price Target$28.00$28.00$23.00
Last Closing Price$23.88$23.88$23.88
Upside/Downside17.25%17.25%-3.69%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 25281--11
Aug, 25281--11
Jul, 25271--10
Jun, 25271--10
May, 25271--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 18, 2025Thomas ShraderBTIG$28.00$18.1054.70%17.25%
Oct 11, 2024Marc GoodmanLeerink Partners$18.00$11.8452.03%-24.62%
Sep 11, 2024Debjit ChattopadhyayH.C. Wainwright$35.00$15.32128.46%46.57%
May 07, 2024Sumant KulkamiCanaccord Genuity$20.00$11.8768.49%-16.25%
Mar 26, 2024Joseph StringerNeedham$22.00$6.50238.46%-7.87%
Mar 26, 2024Sumant KulkamiCanaccord Genuity$21.00$10.9292.31%-12.06%
Nov 14, 2022Needham$25.00$9.33167.95%4.69%
Apr 26, 2021Judah FrommerCredit Suisse$58.00$32.5078.46%142.88%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 18, 2025BTIGBuyBuyhold
Sep 11, 2024Cowen & Co.BuyBuyhold
Sep 11, 2024H.C. WainwrightBuyBuyhold
Jun 28, 2024NeedhamBuyBuyhold
May 07, 2024Canaccord GenuityBuyBuyhold
May 06, 2024WedbushBuyBuyhold
Apr 04, 2024NeedhamUnderperformUnderperformhold
Mar 26, 2024NeedhamBuyBuyhold
Mar 26, 2024Canaccord GenuityBuyBuyhold
Mar 26, 2024Cowen & Co.Buyupgrade

Financial Forecast

EPS Forecast

Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.39$-2.38$-1.65----
Avg Forecast$-2.66$-2.38$-2.03$-2.37$-2.55$-2.07$-1.66
High Forecast$-1.74$-2.26$-2.00$-2.04$-2.06$-0.17$-0.64
Low Forecast$-3.15$-2.48$-2.11$-2.77$-3.20$-3.40$-2.52
Surprise %-10.15%--18.72%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.40M$8.78M$36.55M----
Avg Forecast$11.70M$9.53M$17.42M$20.36M$23.29M$69.31M$108.62M
High Forecast$13.36M$10.87M$18.30M$28.57M$32.69M$97.28M$152.44M
Low Forecast$8.59M$7.83M$15.30M$10.71M$12.26M$36.48M$57.17M
Surprise %6.05%-7.82%109.87%----

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-93.11M$-104.70M$-88.98M----
Avg Forecast$-117.09M$-104.70M$-90.36M$-105.69M$-115.76M$-78.53M$-72.81M
High Forecast$-76.69M$-99.54M$-87.95M$-89.73M$-90.62M$-7.48M$-27.98M
Low Forecast$-138.67M$-109.24M$-92.78M$-121.66M$-140.91M$-149.58M$-111.01M
Surprise %-20.48%--1.53%----

STOK Forecast FAQ

Is Stoke Therapeutics stock a buy?

Stoke Therapeutics stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Stoke Therapeutics is a favorable investment for most analysts.

What is Stoke Therapeutics's price target?

Stoke Therapeutics's price target, set by 15 Wall Street analysts, averages $28 over the next 12 months. The price target range spans from $28 at the low end to $28 at the high end, suggesting a potential 17.25% change from the previous closing price of $23.88.

How does Stoke Therapeutics stock forecast compare to its benchmarks?

Stoke Therapeutics's stock forecast shows a 17.25% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and underperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for Stoke Therapeutics over the past three months?

  • September 2025: 18.18% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 18.18% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 20.00% Strong Buy, 70.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Stoke Therapeutics’s EPS forecast?

Stoke Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.37, marking a 43.64% increase from the reported $-1.65 in 2024. Estimates for the following years are $-2.55 in 2026, $-2.07 in 2027, and $-1.66 in 2028.

What is Stoke Therapeutics’s revenue forecast?

Stoke Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $20.36M, reflecting a -44.31% decrease from the reported $36.56M in 2024. The forecast for 2026 is $23.29M, followed by $69.32M for 2027, and $108.62M for 2028.

What is Stoke Therapeutics’s net income forecast?

Stoke Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-106M, representing an 18.78% increase from the reported $-88.981M in 2024. Projections indicate $-116M in 2026, $-78.531M in 2027, and $-72.811M in 2028.